Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults

International Immunopharmacology

Volumn 9, Issue 5, 2009, Pages 639-644

  Weisman, Leonard E ^a   Fischer, Gerald W ^c   Thackray, Helen M ^c   Johnson, Karen E ^a   Schuman, Richard F ^c   Mandy, George T ^a   Stratton, Beth E ^c   Adams, Karen M ^a   Kramer, William G ^b   Mond, James J ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Kramer Consulting LLC   (United States)

^c Biosynexus Incorporated   (United States)

Author keywords

Chimerized monoclonal antibody; Coagulase negative staphylococci; Immunogenicity; Opsonophagocytic activity; Pharmacokinetics; Safety; Staphylococcus aureus; Staphylococcus epidermidis

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; LIPOTEICHOIC ACID; MONOCLONAL ANTIBODY; PAGIBAXIMAB; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; HYBRID PROTEIN; LIPOPOLYSACCHARIDE; TEICHOIC ACID;

ADULT; ANKLE PAIN; ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOOD SAMPLING; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONSTIPATION; CYSTITIS; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOOT PAIN; GASTROINTESTINAL SYMPTOM; HEADACHE; HIGH RISK POPULATION; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NEUROTOXICITY; NONHUMAN; NORMAL HUMAN; NOSE DISEASE; OPSONIZATION; PAIN; PAINFUL TONGUE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SCRATCHY THROAT; SHOULDER PAIN; SINUS HEADACHE; SKIN ABRASION; SKIN DEFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STUFFY NOSE; THROAT DISEASE; TONGUE DISEASE; TOOTH PAIN; ANIMAL; DRUG EFFECTS; HALF LIFE TIME; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MOUSE; NEUTROPHIL; PATHOLOGY; PHAGOCYTOSIS; STAPHYLOCOCCAL INFECTIONS;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; MALE; MICE; MIDDLE AGED; NEUTROPHILS; PHAGOCYTOSIS; RECOMBINANT FUSION PROTEINS; SERUM BACTERICIDAL TEST; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TEICHOIC ACIDS;

EID: 63549113233     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.02.008     Document Type: Article

References (18)

1. Fanaroff A.A., Korones S.B., Wright L.L., Verter J., Poland R.L., Bauer C.R., et al. Incidence, presenting features, risk factors and significance of late onset septicemia in very low birth weight infants. Pediatr Infect Dis J. 17 (1998) 593-598
2. Gray J.E., Richardson D.K., McCormick M.C., and Goldmann D.A. Coagulase-negative staphylococcal bacteremia among very low birth weight infants: relation to admission illness severity, resource use and outcome. Pediatrics 95 (1995) 225-230
3. Eady E.A., and Cove J.H. Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus-an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis. 16 2 (Apr 2003) 103-124
4. Smith T.L., Pearson M.L., Wilcox K.R., Cruz C., Lancaster M.V., and Robinson-Dunn B. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 340 7 (Feb 1999) 493-501
5. Srinivasan A., Dick J.D., and Perl T.M. Vancomycin resistance in staphylococci. Clin Microbiol Rev 15 3 (July 2002) 430-438
6. Tegnell A. Study of developed resistance due to antibiotic treatment of coagulase-negative staphylococci. Microb Drug Resist vol. 9 No. 1 (Mar 2003) 1-6
7. Weisman L.E., Schuman R.F., Lukomska E., Stinson J.R., Parks O., and Fischer G.W. Effectiveness and pharmacokinetics of an anti-lipoteichoic acid humanized mouse chimeric monoclonal antibody. Pediatric Academic Societies Annual Meeting. Baltimore (May 2001)
8. Ginsburg I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect Dis 2 3 (Mar 2002) 171-179
9. Fischer GW, Cieslak TJ, Wilson SR, Weisman LE, Hemming VG. Opsonic antibodies to Staphylococcus epidermidis: in vitro and in vivo studies using human intravenous immune globulin. J Infect Dis. 1994;169:324-9.
10. Mankarious S., Lee M., Fischer S., Pyun K.H., Ochs H.D., and Oxelius V.A. The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med. 112 5 (Nov 1988) 634-640
11. Azuma J., Kurimoto T., Tsuji S., Mochizuki N., Fujinaga S., and Matsumoto Y. Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother. 10 4 (Aug 1991) 278-285
12. LoBuglio A.F., Wheeler R.H., Trang J., Haynes A., Rogers K., and Harvey E.B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 86 11 (Jun 1989) 4220-4224
13. Solomon A., Waldmann T.A., and Fahey J.L. Clinical and experimental metabolism of normal 6.6 s gamma-globulin in normal subjects and in patients with macroglobulinemia and multiple myeloma. J Lab Clin Med 62 (Jul 1963) 1-17
14. Chow F.S., Benincosa L.J., Sheth S.B., Wilson D., Davis C.B., and Minthorn E.A. Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther. 71 4 (Apr 2002) 235-245
15. Weisman L.E., Fischer G.W., Marinelli P., Hemming V.G., Pierce J.R., and Golden S.M. Pharmacokinetics of intravenous immunoglobulin in neonates. Vox Sang. 57 4 (1989) 243-248
16. Weisman L.E., Fischer G.W., Hemming V.G., and Peck C.C. Pharmacokinetics of intravenous immunoglobulin (Sandoglobulin®) in neonates. Pediatr Infect Dis 5 3 Suppl (May-Jun 1986) S185-188
17. Fanaroff A.A., Korones S.B., Wright L.L., Wright E.C., Poland R.L., and Bauer C.B. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. N Engl J Med vol. 330 (1994) 1107-1113
18. Ballow M., Cates K.L., Rowe J.C., Goetz C., and Desbonnet C. Development of the immune system in very low birth weight (less than 1500 g) premature infants: concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res. 20 (1986) 899-904